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26839
Dupilumab with topical corticosteroids results in rapid and
sustained improvement in adults with moderate-to-severe atopic
dermatitis across all anatomic regions over 52 weeks
Andrew Blauvelt, Oregon Medical Research Center, Portland, OR;
Marjolein de Bruin-Weller, University Medical Center Utrecht, Utrecht,
Netherlands; Melinda Gooderham, SKiN Centre for Dermatology,
Peterborough, ON, Canada; David M. Pariser, Eastern Virginia Medical School
and Virginia Clinical Research Inc, Norfolk, VA; Eric L. Simpson, Oregon Health &
Science University, Portland, OR; Takafumi Etoh, Tokyo Teishin Postal Services
Agency Hospital, Tokyo, Japan; Zhen Chen, Regeneron Pharmaceuticals Inc,
Tarrytown, NY; Debra Sierka, Sanofi Genzyme, Cambridge, MA; Brad Shumel,
Regeneron Pharmaceuticals Inc, Tarrytown, NY
Background: Atopic dermatitis (AD) affects different anatomic regions; some adults
may exhibit more localized AD, such as head and neck involvement. We analyzed the
extent of improvement in AD signs across different anatomic regions at Week 52
using data from the phase 3 dupilumab trial, LIBERTY AD CHRONOS
(NCT02260986).
Methods: Adults with moderate-to-severe AD were randomized 1:3 to dupilumab
300 mg with topical corticosteroids (TCS) every 2 weeks (q2w+TCS) or
placebo+TCS for 52 weeks. Least squares mean percent change (standard error)
in Eczema Area and Severity Index by anatomic region is reported.
Results: 421 patients were analyzed (q2w+TCS, n ¼ 106; placebo+TCS, n ¼ 315).
Significant improvements in all signs in all body regions occurred as early as Week 4
(P\.05). Erythema improvement at Week 52 (q2w+TCS vs placebo+TCS) was: head
and neck 65.1(4.9)/35.1(2.9); trunk 72.7(4.1)/41.7(2.5); upper extremities
70.5(4.1)/39.2(2.5);
and
lower
extremities
75.7(5.1)/40.9(3.1).
Infiltration/papulation improvement at Week 52 (q2w+TCS vs placebo+TCS) was:
head and neck 66.0(5.9)/40.0(3.5); trunk 78.1(4.4)/44.2(2.6); upper extremities 76.6(4.2)/41.1(2.5); and lower extremities 80.4(6.0)/42.1(3.6).
Excoriation improvement at Week 52 (q2w+TCS vs placebo+TCS) was: head and
neck 73.4(5.9)/48.0(3.6); trunk 85.5(4.6)/45.2(2.8); upper extremities
80.6(4.9)/42.0(2.9);
and
lower
extremities
85.7(5.1)/40.7(3.0).
Lichenification improvement at Week 52 (q2w+TCS vs placebo+TCS) was: head
and neck 74.0(6.1)/39.8(3.6); trunk 81.1(4.5)/45.4(2.8); upper extremities
75.5(4.5)/43.3(2.7);
and
lower
extremities
81.6(4.6)/47.1(2.8).
Improvements were significant (P \ .0001) for all Week 52 comparisons.
Dupilumab was generally well tolerated with an acceptable safety profile.
Conclusion: In adults with moderate-to-severe AD, dupilumab q2w+TCS showed
rapid, significant, and sustained improvement in AD signs across all anatomic
regions compared with placebo+TCS.

26845
Toward novel depigmenting agents through repurposing existing drugs
Juris Germanas, MD, PhD, Department of Dermatology, University of
Maryland School of Medicine; Kyonghee Kim, PhD, Maryland
Dermatology Associates; Tomas Germanas, Maryland Dermatology Associates
Inhibitors of the enzyme tyrosinase have found clinical utility as agents to treat
disorders of hyperpigmentation of the skin. Potential cellular toxicity and carcinogenicity of currently available tyrosinase inhibitors motivates finding safer and more
effective alternatives. ‘‘Repurposed’’ drugs have recently attracted attention due to
the possibility of finding safe and effective medical treatments with less time spent in
early stage drug development. We report the identification and characterization of
potent tyrosinase inhibitors that are ‘‘repurposed’’ existing drugs. Para-acetaminophenols, exemplified by the anti-inflammatory agent acetaminophen, displayed
inhibitory activity against mushroom tyrosinase. Detailed analysis of enzyme
kinetics in the presence of acetaminophen showed that it acts as a noncompetitive
inhibitor. Further, acetaminophen behaved as an alternative substrate of the enzyme.
Substituted analogs of acetaminophen were also effective inhibitors, but behaved as
competitive inhibitors. Another class of approved drugs that inhibited the enzyme
were found to display very potent inhibition of tyrosinase, with a Ki of 900
nanomolar. Kinetic analysis revealed this class of molecules acted as competitive
inhibitors, with no evidence of undergoing chemical transformation by tyrosinase or
enzyme inactivation. This class of molecules likely inhibits tyrosinase by coordinating with a copper ion in the enzyme active site. This type of strong and specific
interaction with tyrosinase may make drugs of this class clinically useful as skin
whitening agents.
Commercial Disclosure: None identified.

Commercial Disclosure: Research sponsored by Sanofi & Regeneron
Pharmaceuticals, Inc. Medical writing assistance provided by Luke Shelton
PhD, of Excerpta Medica, funded by Sanofi Genzyme & Regeneron
Pharmaceuticals, Inc.

26842
Long-term proactive management with Cal/BD foam is beneficial
for all patients with psoriasis irrespective of baseline
characteristics
Mark Lebwohl, MD, Department of Dermatology, Icahn School of
Medicine at Mount Sinai, New York, NY; Marie Holst Mørch, MS, LEO Pharma
Ballerup, Denmark
Introduction: The Phase III PSO-LONG study (NCT02899962) demonstrated superior efficacy of proactive (PM) vs reactive management (RM) using calcipotriene
0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam in adults with psoriasis.
Here we evaluate whether certain baseline parameters had an effect on time to first
relapse (TTFR), number of relapses and assessed interactions between treatment
effect and baseline parameters.
Methods: PSO-LONG included an initial 4-week open-label phase (once-daily Cal/BD
foam) and a 52-week, maintenance phase where patients were randomized to twiceweekly Cal/BD (PM) or vehicle foam (RM), with 4-weeks once-daily Cal/BD foam
rescue treatment for relapse. The following baseline parameters were analyzed
using a stepwise variable selection procedure: body surface area, modified-Psoriasis
Area Severity Index (mPASI), Physician’s Global Assessment (PGA), body mass
index, age, gender, dermatology life quality index and duration of psoriasis.
Continuous variables were divided into groups based on standard criteria.
Results: Overall, the effect of treatment on TTFR did not vary across any baseline
parameters. Variables with a significant effect on TTFR were: treatment group
(Hazard Ratio [HR]: 0.56; P \.001); PGA (moderate vs mild HR: 1.42; P ¼.07; severe
vs mild HR: 2.32; P ¼ .003); mPASI moderate vs mild (HR: 1.19; P ¼ .16; severe vs
mild HR: 1.78; P ¼ .002); gender (female vs male HR: 1.25; P ¼ .03). The effect of
treatment on total number of relapses will also be presented.

26856
Proliferative nodule resembling angiomatoid Spitz with pronounced degenerative atypia arising within a giant congenital
nevus
Taylor L. Braunberger, MD, Department of Dermatology, Henry Ford
Hospital; Madeline Adelman, BS, Wayne State University School of Medicine; Tor
A. Shwayder, MD, Department of Dermatology, Henry Ford Hospital; Loren E.
Clarke, MD, Myriad Genetics, Inc; Ben J. Friedman, MD, Department of
Dermatology, Henry Ford Hospital

Conclusion: The effect of long-term PM vs RM with Cal/BD foam was not dependent
on baseline parameters. Patients with more severe disease at baseline had greater
benefit from PM than those with milder disease.

Proliferative nodules arising within congenital melanocytic nevi present a diagnostic
challenge for dematopathologists given their close resemblance to melanoma. In
difficult cases, ancillary molecular tests can be used to better exclude the possibility
of malignancy. We report case of a biopsy and subsequent excision of an unusual
proliferative nodule with overlapping features of angiomatoid Spitz tumor and
ancient melanocytic nevus which demonstrated normal findings on both chromosomal microarray and a gene expression profiling assay. Our case is noteworthy
given its striking resemblance to what has been reported for an angiomatoid Spitz
tumor. To our knowledge, this particular morphologic subset of Spitz has been
described primarily in the context of spontaneous melanocytic tumors arising de
novo outside the context of a congenital lesion. The pathology showed bizarre
cytological features along with a myxoid and highly vascularized stroma which is
thought to represent degenerative atypia characteristic of an ‘‘ancient nevus.’’ The
lesions described as ancient nevi have some overlapping stromal features with
angiomatoid Spitz tumors. A low proliferation index and paucity of mitotic figures is
characteristic of these neoplasms. We hypothesize that continued host response to
the lesion may be responsible for inducing the observed cytological and stromal
derangement. Interestingly, these changes increased from the time of biopsy to the
excision. Future studies should aim to define the genetic and immunologic signature
of these lesions to help predict prognosis. The relationship between angiomatoid
Spitz tumor, ancient change, and regressing nevi should also be investigated.

Commercial Disclosure: 100% is paid for by LEO Pharma.
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